Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trinocard
- Development stage
- Unknown
- Lead developer
- Bruno Farmaceutici
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Trinocard** is an oral fixed-dose tablet containing the angiotensin-converting enzyme inhibitor ramipril, the dihydropyridine calcium-channel blocker amlodipine, and the HMG-CoA reductase inhibitor atorvastatin. In Italy, it is authorized as substitution therapy for adults with hypertension associated with primary hypercholesterolemia or mixed hyperlipidemia who are already adequately controlled on the same doses of the three individual medicines taken concomitantly. ([api.aifa.gov.it](https://api.aifa.gov.it/aifa-bdf-eif-be/1.0.0/organizzazione/2879/farmaci/48741/stampati?ts=RCP))
- Brand names
- Trinocard
- Other names
- ramipril + amlodipina + atorvastatinaramipril + amlodipine + atorvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ACE (Angiotensin Converting Enzyme)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on Trinocard.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trinocard.